Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
WAYNE, Pa., March 09, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that, globally, 250,000 patients have been treated with the UroLift ® System, a proven, minimally ...
NeoTract, Inc., today announced the successful results of the 206-patient L.I.F.T. IDE Study, a multi-center, randomized, blinded study in patients with Benign Prostatic Hyperplasia (BPH). All primary ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Sponsored content: Enlarged prostate affects ...
Physician brings non-surgical outpatient prostate procedure to McLaren Northern Michigan, providing quicker recovery times. Featured in the 2021 issue of MyNorth Medical Insider. When Bryan Shumaker, ...
The committee concluded that UroLift is clinically effective, with sustained relief of lower urinary tract symptoms up to 5 years after treatment. It is implanted using a minimally invasive procedure.
GRESHAM, Ore. — A new FDA-approved outpatient procedure for men 55 and over who suffer from frequent urination promises immediate relief from an enlarge prostate without painful surgery or a long ...
WAYNE, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that the U.S. Food and Drug Administration (FDA) has granted the company an expanded indication for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results